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Background: Bezafibrate is mainly used to treat hypertriglyceridemia. Studies have reported that bezafibrate also
improves type 2 diabetes mellitus, but the mechanism has not been fully elucidated. We performed euglycemic
hyperinsulinemic clamps (glucose clamp) and meal tolerance tests (MTT) to examine the effects of bezafibrate on
insulin resistance in patients with type 2 diabetes mellitus.
Methods: Twelve Japanese patients with type 2 diabetes mellitus and dyslipidemia (mean age: 59.5 years; fasting
plasma glucose: 7.95 mmol/L; hemoglobin A1c [HbA1c]: 7.3%; body mass index: 26.5 kg/m2) underwent a glucose
clamp and MTT before and after 12 weeks of treatment with 400 mg/day bezafibrate. The glucose infusion rate was
measured during the glucose clamp. The patients took a test meal (460 kcal) in the MTT. Plasma glucose and
immunoreactive insulin levels were measured at 0 (fasting), 30, 60, 120, and 180 min. Serum C-peptide immunoreactivity,
serum lipids, and liver function markers were also measured during the MTT.
Results: Bezafibrate significantly increased the mean glucose infusion rate from 5.78 ± 1.94 to 6.78 ± 2.52 mg/kg/min
(p < 0.05). HbA1c improved from 7.30 ± 0.55% to 7.02 ± 0.52% (p < 0.05). In the MTT, fasting plasma glucose
decreased from 7.95 ± 1.15 to 6.98 ± 1.07 mmol/L (p < 0.05). The area under the plasma glucose curve from 0 to
180 min decreased significantly from 29.48 ± 5.07 to 27.12 ± 3.98 mmol/h/L (p < 0.05), whereas immunoreactive
insulin was unchanged. Furthermore, bezafibrate also significantly improved serum lipids, with decreases in
triglyceride levels from 1.84 ± 0.88 to 1.14 ± 0.41 mmol/L (p < 0.05), low-density lipoprotein cholesterol levels from
3.56 ± 0.83 to 2.92 ± 0.55 mmol/L (p < 0.05), and remnant-like particle cholesterol levels decreased from 0.25 ± 0.16
to 0.14 ± 0.06 mmol/L (p < 0.05), and increases in high-density lipoprotein cholesterol levels from 1.50 ± 0.24 to
1.66 ± 0.29 mmol/L (p < 0.05).
Conclusions: Bezafibrate improved glucose intolerance and peripheral insulin resistance in these Japanese patients
with type 2 diabetes mellitus and dyslipidemia. Therefore, bezafibrate could be used to treat insulin resistance in
patients with type 2 diabetes mellitus and dyslipidemia.
Trial registration: University Hospital Medical Information Network (UMIN) Clinical Trials Registry, UMIN000012462.
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Type 2 diabetes mellitus is a heterogeneous disease char-
acterized by insulin resistance and defective insulin se-
cretion [1]. There are currently two classes of drugs
available to treat insulin resistance, thiazolidinediones
and metformin; new insulin sensitizers are required.
Bezafibrate is currently mainly used to treat hypertriglyc-
eridemia. Bezafibrate was found to reduce the incidence
of coronary artery disease, especially non-fatal myocar-
dial infarction, in patients with high baseline triglycer-
ides (≥200 mg/dl) or with metabolic syndrome [2,3], as
well as to reduce the incidence and delay the onset of
type 2 diabetes in obese patients [4]. Furthermore, beza-
fibrate was associated with a lower risk of incident
diabetes compared with other fibrates (ciprofibrate,
clofibrate, gemfibrozil, and fenofibrate) [5]. In the Japan
bezafibrate clinical effectiveness and tolerability (J-
BENEFIT) study, a large-scale study of 3316 patients
with type 2 diabetes mellitus and dyslipidemia, adminis-
tration of 200–400 mg/day of bezafibrate for 24 weeks
decreased hemoglobin A1c (HbA1c) from 7.69% to
7.22% and fasting blood glucose levels from 9.00 to
7.81 mmol/L [6]. These results indicate that bezafibrate
is also effective for the treatment of type 2 diabetes
mellitus.
The gold standard for assessing insulin resistance in
human is the euglycemic hyperinsulinemic clamp (glu-
cose clamp). In the glucose clamp, most of the infused
glucose is taken up by peripheral tissues, primarily
muscle [7]. Under the steady-state conditions of euglyce-
mia, the glucose infusion rate (GIR) is a measure of tis-
sue sensitivity to exogenous insulin [8]. A previous study
of nondiabetic men with combined hyperlipidemia
revealed that bezafibrate did not improve insulin sensi-
tivity assessed by glucose clamps [9]. A study of six pa-
tients with type 2 diabetes mellitus also revealed that
bezafibrate did not change peripheral insulin sensitivity
assessed by glucose clamps [10]. However, that study
was small, involving only six patients, and there are no
other reports describing the effects of bezafibrate on in-
sulin sensitivity, assessed by glucose clamps, in patients
with type 2 diabetes mellitus.
Patients with type 2 diabetes mellitus generally have
higher serum triglyceride (TG) and low-density lipopro-
tein cholesterol (LDL-C) levels and lower high-density
lipoprotein cholesterol (HDL-C) levels than people with-
out diabetes [11]. Furthermore, serum TG, LDL-C, and
HDL-C levels are worse when HbA1c is high [12]. Intra-
myocellular lipid levels are inversely associated with
insulin sensitivity [13].
Based on these results, we hypothesized that beza-
fibrate improves glucose intolerance by improving
hypertriglyceridemia and skeletal muscle insulin resist-
ance in patients with type 2 diabetes mellitus. To testthis hypothesis, we performed glucose clamps and meal
tolerance tests (MTT) to examine the effects of be-
zafibrate on insulin resistance, glucose metabolism, and




The subjects were recruited from the outpatient clinic at
Tottori University Hospital between January 2009 and Au-
gust 2012. The entry criteria included patients with type 2
diabetes mellitus and dyslipidemia. Patients with pancre-
atic disease, liver disease, renal failure, or those taking dia-
betogenic medications, such as corticosteroids, were
excluded from the study. Consecutive subjects previously
diagnosed type 2 diabetes mellitus and dyslipidemia were
chosen. Type 2 diabetes mellitus was diagnosed based on
the criteria of the World Health Organization [14]. Dyslip-
idemia was defined as follows: TG levels ≥1.7 mmol/L,
and/or LDL-C levels ≥3.6 mmol/L, and/or HDL-C
levels ≤1.0 mmol/L. Table 1 shows the characteristics and
treatments of the patients at baseline. There were five
males and seven females. Their mean age was 59.5 years.
Two patients were on diet therapy alone and 10 patients
were being treated with one or more oral hypoglycemic
agents, including sulfonylurea (2 patients), glinides (3),
metformin (3), α-glucosidase inhibitors (5), and dipeptidyl
















Figure 1 Individual and mean changes in GIR at baseline and
after 12 weeks of treatment with bezafibrate. ♦ =mean GIR; ● =
individual GIR (n = 12). GIR = glucose infusion rate. *p < 0.05 vs.
baseline (paired t test).
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None of the patients were using thiazolidinediones or in-
sulin. Regarding hypolipidemic agents, statin and ezeti-
mibe were not administered to the same patients.
All of the patients were treated with 400 mg bezafi-
brate twice daily for 12 weeks. There were no changes in
lifestyle interventions or medications during the study
period. The patients underwent the glucose clamps and
MTTs before and after 12 weeks of treatment with
bezafibrate.
HbA1c was measured by high-performance liquid
chromatography and was converted to National Glycohe-
moglobin Standardization Program (NGSP) values using
the following officially certified equation: NGSP (%) =
1.02 × Japan Diabetes Society (JDS, %) + 0.25% [15]. The
reverse equation is as follows: JDS (%) = 0.980 × NGSP
(%) − 0.245%. HbA1c (NGSP) values were also converted
to International Federation of Clinical Chemistry values
(mmol/mol) using the HbA1c converter developed by
Diabetes UK (Macleod House, London, UK).
This study was approved by the Ethical Committee of
the Faculty of Medicine, Tottori University. Informed
consent was obtained from the patients on the basis of a
procedure officially approved by the Ethical Committee.
Glucose clamp
The glucose clamps were conducted as previously de-
scribed [16-18]. Briefly, the patients fasted overnight
from 21:00 to 09:00 h before each test and visited the
clinic in the morning. An antecubital vein was cannu-
lated to administer the infusate, and a dorsal vein was
cannulated and kept warm to facilitate venous sampling
and provide arterialized venous blood. The glucose
clamp was performed to determine insulin sensitivity in
peripheral tissue [8] using an artificial endocrine pan-
creas (STG 22; Nikkiso, Shizuoka, Japan). A primed-
constant infusion of insulin (100 mU/m2/min) and
computer-controlled exogenous infusion of glucose solu-
tion were used to achieve steady-state plasma insulin
levels and maintain plasma glucose levels at 5.2 mmol/L
(95 mg/dL). Using an identical insulin infusion, previous
studies have shown that the steady-state plasma insulin
level is 1200 pmol/L in patients with type 2 diabetes
mellitus [19,20]. The steady-state GIR was calculated at
90–120 min and the mean GIR during that period was
used as a marker of peripheral insulin sensitivity.
MTT
The MTT was conducted as previously described
[16-18] on a different day, generally 2–3 days before the
glucose clamp. Briefly, the patients were fasted overnight
from 21:00 to 09:00 h before each test. The patients vis-
ited the clinic in the morning and consumed a test meal
prepared by the Japan Diabetes Society (460 kcal; 15%protein, 35% fat, 50% carbohydrates, and 1.6 g salt) [21].
Plasma glucose and immunoreactive insulin (IRI) were
measured at 0 (fasting), 30, 60, 120, and 180 min after the
test meal. Serum C-peptide immunoreactivity, TG, and
plasma remnant-like particle cholesterol (RLP-C) levels
were measured at 0 (fasting) and 120 min. HbA1c, total
cholesterol, LDL-C, HDL-C, high-sensitivity C-reactive
protein, adiponectin, aspartate aminotransferase, alanine
aminotransferase (ALT), and γ-glutamyltranspeptidase
isozyme (γ-GTP) levels were measured using fasting sam-
ples. Plasma glucose levels were measured using the glu-
cose oxidase method. Plasma insulin and C-peptide
immunoreactivity levels were measured using chemilu-
minescent immunoassays (human insulin and C-peptide
immunoreactivity CLIA kit; Kyowa Medex, Tokyo,
Japan). Plasma insulin was defined as IRI. Plasma adipo-
nectin levels were measured using an enzyme-linked
immunosorbent assay (human adiponectin ELISA kit;
Otsuka, Tokyo, Japan). RLP-C levels were measured
using a homogeneous assay (MetaboLead RemL-C kit:
Kyowa Medex). High-sensitive C-reactive protein was
measured by nephelometry (N-Latex CRP II kit; Siemens
Healthcare Diagnostics, Tokyo, Japan).
Statistical analysis
Data are expressed as means ± standard error of the
mean. Baseline data were compared with those obtained
after treatment using paired t tests. Statistical signifi-
cance was defined as p < 0.05. SPSS software version
15.0 (SPSS, Chicago, IL, USA) was used for statistical
analyses.
Results
Figure 1 shows the changes in the steady-state mean
GIR in the glucose clamps performed before and after
12 weeks of treatment with bezafibrate. The GIR signifi-
cantly increased from 5.78 mg/kg/min before bezafibrate
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The mean plasma IRI level was 1380 ± 538 pmol/L at
steady-state during the glucose clamp.
Table 2 shows the clinical characteristics of the subjects
at baseline and after 12 weeks of treatment with be-
zafibrate. HbA1c (from 7.30% to 7.02%) and fasting
plasma glucose (FPG) levels (from 7.95 to 6.98 mmol/L)
decreased significantly during this treatment period
(p < 0.05). The homeostatic model assessment of insulin
resistance (HOMA-IR) tended to improve (from 2.66 to
2.20, p = 0.08). Regarding lipid levels, TG (p < 0.01), RLP-CTable 2 Results of the MTTs performed before and after
12 weeks of treatment with bezafibrate
Baseline 12 weeks p
HbA1c (NGSP) (%) 7.30 ± 0.55 7.02 ± 0.52 <0.05
HbA1c (NGSP) (mmol/mol) 54.5 ± 5.6 51.6 ± 5.3 <0.05
FPG (mmol/L) 7.95 ± 1.15 6.98 ± 1.07 <0.01
HOMA-IR 2.66 ± 1.42 2.20 ± 0.94 0.08
HOMA-β 38.97 ± 34.28 46.44 ± 28.59 0.12
Matsuda index 5.59 ± 2.04 5.98 ± 2.48 0.47
Insulinogenic index 0.92 ± 0.81 0.67 ± 0.69 0.18
IRI (pmol/L) Fasting 54.7 ± 29.4 51.8 ± 23.5 0.51
120 min* 257.1 ± 153.0 292.2 ± 176.1 0.18
CPR (nmol/L) Fasting 0.55 ± 0.25 0.50 ± 0.14 0.28
120 min* 1.54 ± 0.52 1.56 ± 0.42 0.82
TG (mmol/L) Fasting 1.84 ± 0.88 1.14 ± 0.41 <0.01
120 min* 2.13 ± 0.97 1.47 ± 0.40 <0.01
RLP-C (mmol/L) Fasting 0.25 ± 0.16 0.12 ± 0.05 <0.05
120 min* 0.26 ± 0.16 0.14 ± 0.06 <0.05
TC (mmol/L) 5.83 ± 1.03 5.30 ± 0.60 <0.05
LDL-C (mmol/L) 3.56 ± 0.83 2.92 ± 0.55 <0.05
HDL-C (mmol/L) 1.50 ± 0.24 1.66 ± 0.29 <0.05
hs-CRP (mg/dl) 0.11 ± 0.10 0.09 ± 0.12 0.38
Adiponectin (μg/mL) 7.81 ± 2.52 8.37 ± 3.90 0.31
AST (IU/L) 32.3 ± 21.7 28.9 ± 19.7 0.05
ALT (IU/L) 39.8 ± 25.8 28.8 ± 19.6 <0.01
γ-GTP (IU/L) 66.5 ± 56.2 30.7 ± 18.2 <0.05
BMI (kg/m2) 26.5 ± 3.1 26.2 ± 2.9 0.14
Waist circumference (cm) 91.8 ± 7.6 93.5 ± 9.2 0.14
Data are mean ± standard deviation.
TC, LDL-C, HDL-C, RLP-C, hs-CRP, adiponectin, AST, ALT, and γ-GTP were
measured using fasting blood samples.
*Measured at 120 min after the test meal.
HbA1c = hemoglobin A1c; NGSP = National Glycohemoglobin Standarization
Program; FPG = fasting plasma glucose; HOMA-IR = homeostatic model
assessment of insulin resistance; HOMA-β = homeostasis model assessment of β
cell function; IRI = immunoreactive insulin; CPR = C-peptide immunoreactivity;
TG = triglycerides; RLP-C = remnant-like particle cholesterol; LDL-C = low-density
lipoprotein cholesterol; HDL-C = high-density lipoprotein cholesterol;
hs-CRP = high-sensitivity C-reactive protein; AST = aspartate aminotransferase;
ALT = alanine aminotransferase; γ-GTP = γ-glutamyltranspeptidase; BMI = body
mass index.(p < 0.05), total cholesterol (p < 0.05), and LDL-C (p < 0.05)
levels decreased significantly and HDL-C (p < 0.05) levels
increased significantly between baseline and 12 weeks of
treatment. Regarding liver function markers, ALT (p < 0.01)
and γ-GTP levels (p < 0.05) decreased significantly after
treatment. Body mass index and waist circumference did
not increase after bezafibrate treatment.
Figures 2 and 3 show the changes in plasma glucose and
IRI levels in the MTTs performed before and after
12 weeks of treatment with bezafibrate. In addition to a
decrease in FPG, plasma glucose levels at 180 min after
the meal decreased significantly from 9.30 ± 1.85 to 8.05 ±
1.84 mmol/L (p < 0.01). The area under the plasma glu-
cose curve from 0 to 180 min decreased significantly
from 29.5 ± 5.1 to 27.1 ± 4.0 mmol/h/L (p < 0.05). There
were no significant changes in IRI, including the area
under the IRI curve from 0 to 180 min.
Discussion
In this study, bezafibrate improved the GIR by 17%
(from 5.78 to 6.78 mg/kg/min) in glucose clamps in pa-
tients with type 2 diabetes mellitus and dyslipidemia.
Bezafibrate also improved glucose intolerance, as shown
by decreases in HbA1c and FPG, similar to the J-
BENEFIT study [6]. In the steady-state euglycemic
condition, the GIR is indicative of skeletal muscle insulin
resistance. Our results indicate that bezafibrate improved
skeletal muscle insulin resistance without increasing
insulin secretion.
HOMA-IR, which was developed by Turner et al., is
an index of insulin resistance, predominantly hepatic in-
sulin resistance [22]. A previous study of 168 patients
with type 2 diabetes mellitus revealed that HOMA-IR
and insulin were not altered by bezafibrate [23]. In the J-
BENEFIT study [6], bezafibrate improved (i.e. decreased)
HOMA-IR from 4.46 to 3.38 in patients with type 2 dia-
betes mellitus and dyslipidemia. Another study showed
that bezafibrate attenuated the progression of insulin
resistance by evaluating HOMA-IR in patients with cor-
onary artery disease [24]. In our study, bezafibrate sig-
nificantly decreased liver function markers, especially
ALT and γ-GTP. HOMA-IR tended to improve and IRI
did not change after 12 weeks of treatment compared
with before treatment. These results suggest that bezafi-
brate improved insulin resistance in the liver, and in
skeletal muscle without increasing insulin secretion.
Peroxisome proliferator-activated receptor subtypes
(PPARs) are members of the nuclear receptor superfam-
ily [25]. There are three PPARs; PPARα, PPRAδ, and
PPARγ [26]. PPARα is highly expressed in hepatocytes,
cardiomyocytes, enterocytes and the proximal tubule
cells of kidney. PPARδ is highly expressed in skeletal
muscle, and PPARγ is mainly expressed in adipose tis-






















































Figure 2 Plasma glucose levels and IRI in the MTTs before and after 12 weeks of treatment with bezafibrate. ● =mean values at
baseline; ○ =mean values after 12 weeks of treatment with bezafibrate (n = 12). IRI = immunoreactive insulin; MTT =meal tolerance test;
PG = plasma glucose. **p < 0.01 vs. baseline (paired t test).
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glucose and lipid homeostasis [26].
Fenofibrate is another fibrate used to treat hypertri-
glyceridemia. The large-scale Fenofibrate Intervention
and Event Lowering in Diabetes (FIELD) study revealed
that fenofibrate did not improve HbA1c in patients with
type 2 diabetes mellitus and hyperlipidemia [30]. Fenofi-
brate is a PPARα-specific agonist, whereas bezafibrate is
a pan-PPAR agonist that activates all three PPAR iso-
forms [31]. It was reported that activation of all three
isoforms is better than activation of a single isoform in
terms of improving insulin resistance [32]. Bezafribrate
is also associated with weaker mitochondrial toxicity
than fenofibrate [33]. Plasma fatty acids are an important
metabolic substrate in skeletal muscle [34] and skeletal
muscle is responsible for approximately 80% of insulin-
stimulated glucose uptake [29]. Bezafibrate normalizes
the fatty acid composition of skeletal muscle, which is
closely related to insulin resistance [35]. Intramyocellular
lipid levels are inversely associated with insulin sensitivityFigure 3 Areas under the plasma glucose and IRI curves from 0 to 18
with bezafibrate (n = 12). AUC0–180 min = area under the curve from 0 to
vs. baseline (paired t test).[13], and an increase in skeletal muscle TG content
due to hypertriglyceridemia exacerbates insulin resistance.
Therefore, by activating PPARα, PPARδ, and PPARγ
together and reducing TG in skeletal muscles, bezafibrate
might improve glucose intolerance and insulin resistance
in skeletal muscle.
Bezafibrate was reported to improve fatty liver and
non-alcoholic fatty liver disease in patients with type 2
diabetes [36]. The dual PPARα and PPARδ agonist
GFT505 was reported to suppress endogenous glucose
production and improve hepatic insulin sensitivity [37].
An improvement in fatty liver and co-activation of
PPARα and PPARδ is expected to contribute to the
improvement in hepatic insulin sensitivity. However,
to accurately measure hepatic insulin sensitivity, it is
necessary to use a radioisotope [38,39]. Unfortunately,
it is difficult to perform studies using radioisotopes in
subjects at our institute. Further studies are necessary
to examine the direct effects of bezafibrate on hepatic
insulin sensitivity.0 min in the MTT at baseline and after 12 weeks of treatment
180 min; IRI = immunoreactive insulin; PG = plasma glucose. *p < 0.05
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resistance, thiazolidinediones and metformin. Prior stud-
ies have reported the effects of treatment with a thiazoli-
dinedione or metformin on the GIR in glucose clamps.
For example, one study showed that 12 weeks of treat-
ment with pioglitazone increased the GIR from 8.2 to
9.2 mg/kg/min in patients with type 2 diabetes mellitus
[19]. Similarly, 3 months of treatment with low-dose
metformin (750 mg/day) increased the GIR from 6.24 to
7.82 mg/kg/min in obese Japanese patients with type 2
diabetes mellitus [40]. In our study, bezafibrate increased
the GIR from 5.78 to 6.78 mg/kg/min, and had similar
effects to pioglitazone and metformin in terms of im-
proving peripheral insulin resistance. Moreover, bezafi-
brate did not result in weight gain, unlike pioglitazone.
Furthermore, in the present study, three patients were
administered 750 mg/day or 500 mg/day metformin. In
these three patients, bezafibrate increased the GIR from
5.15 to 7.11 mg/kg/min while continuing metformin.
These results indicate that bezafibrate has additive
effects on improving insulin sensitivity in metformin-
treated patients. Meanwhile, some adverse effects of
metformin and thiazolidinediones have been reported.
Metformin is associated with gastrointestinal symptoms,
such as diarrhea or nausea. Lactic acidosis may also
occur albeit rarely in metformin-treated patients. Thia-
zolidinedione, as PPARγ-specific agonists, can cause
water retention, weight gain, peripheral edema, and con-
gestive heart failure. Selective overexpression of a consti-
tutively active form of PPARδ in mouse adipose tissue
induces significant weight loss and protects against high-
fat diet-induced obesity and dyslipidemia [41]. As a pan-
PPAR agonist, bezafibrate can simultaneously improve
insulin sensitivity by activating PPARγ and attenuate
weight gain by activating PPARδ [42]. By activating
PPARδ, it is thought that bezafibrate therapy does not
induce weight gain.
Some large-scale studies have also examined the safety
of bezafibrate. For example, in the J-BENEFIT study,
adverse drug reactions occurred in 5.1% of bezafibrate-
treated patients, with increased blood creatine phospho-
kinase (0.8%), blood creatinine (0.8%), blood urea (0.5%),
renal impairment (0.3%) and asparate aminotransferase
(0.3%) being the most common events [6]. Similarly, in
the Japanese safety and efficacy of long-term combin-
ation therapy with bezafibrate and ezetimibe in patients
with dyslipidemia study (J-COMPATIBLE), adverse drug
reactions occurred in 6.4% of patients treated with the
combination of bezefibrate and ezetimibe [43]. In our
small study involving 12 patients, there were no adverse
drug reactions during treatment with bezafibrate.
Our study has several limitations, including the small
number of patients, the lack of a control group, and the
use of various oral hypoglycemic agents in combinationwith bezafibrate during the 12-week treatment period.
Because only 12 subjects participated in this study, our
results require confirmation in a larger study. The effect
of bezafibrate on insulin secretion was assessed by calcu-
lating Matsuda and insulinogenic indices from MTTs.
Both indices were not significantly affected, suggesting
that bezafibrate does not alter insulin secretion. Indeed,
bezafibrate did not change IRI levels in the MTTs from
0 to 180 min. However, because the Matsuda and insuli-
nogenic indices were originally derived from the results
of OGTTs, they may not be appropriate for assessing
insulin resistance and acute insulin secretion during
MTTs. Despite these limitations, we consider that our
findings indicate that bezafibrate improves insulin
resistance.Conclusions
Bezafibrate improves glucose intolerance in patients with
type 2 diabetes mellitus and dyslipidemia. The increase
in the GIR in glucose clamps indicates that bezafibrate
improves peripheral insulin resistance, particularly in
skeletal muscle. These results suggest that bezafibrate
could be used to treat insulin resistance in patients with
type 2 diabetes mellitus and dyslipidemia.
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